• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Number needed to treat: a descriptor for weighing therapeutic options.

作者信息

Wen Lonnie, Badgett Robert, Cornell John

机构信息

South Texas Veterans Health Care System (STVHCS), San Antonio, TX, USA.

出版信息

Am J Health Syst Pharm. 2005 Oct 1;62(19):2031-6. doi: 10.2146/ajhp040558.

DOI:10.2146/ajhp040558
PMID:16174840
Abstract

PURPOSE

The utility and limitations of the number needed to treat (NNT) are described and compared with those of alternative descriptors of therapeutic yield.

SUMMARY

Pharmacists, physicians, and patients are more likely to launch interventions based on relative measures of therapeutic yield. The NNT is a simple way to express the absolute therapeutic yield of an intervention. It is essential to take baseline risk and length of follow-up into account when calculating and interpreting absolute or relative measures of therapeutic yield. Patients may have difficulty understanding what the NNT tells them about the benefits and harms associated with an intervention, and confidence intervals for the NNT can be difficult to interpret. Relative measures of benefits are advantageous for comparing benefits across populations with different risks. The use of absolute measures to describe therapeutic options leads to more conservative decision-making and is potentially more useful. Among the absolute measures, the absolute risk reduction may be easier to understand than the NNT. These measures are most helpful when the best options are not clear or when patient input is needed. Personal digital assistants and Web-based tools can assist with calculations.

CONCLUSION

The NNT is a useful measure but is influenced by numerous variables and may not be easily understood by patients.

摘要

相似文献

1
Number needed to treat: a descriptor for weighing therapeutic options.
Am J Health Syst Pharm. 2005 Oct 1;62(19):2031-6. doi: 10.2146/ajhp040558.
2
Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).在低密度脂蛋白胆固醇水平低且高敏C反应蛋白升高的男性和女性中,使用瑞舒伐他汀预防首次心血管事件和死亡的需治疗人数:他汀类药物用于预防的依据:一项评估瑞舒伐他汀的干预试验(JUPITER)
Circ Cardiovasc Qual Outcomes. 2009 Nov;2(6):616-23. doi: 10.1161/CIRCOUTCOMES.109.848473. Epub 2009 Sep 22.
3
The effect of alternative summary statistics for communicating risk reduction on decisions about taking statins: a randomized trial.用于传达风险降低信息的替代汇总统计量对他汀类药物使用决策的影响:一项随机试验。
PLoS Med. 2009 Aug;6(8):e1000134. doi: 10.1371/journal.pmed.1000134. Epub 2009 Aug 25.
4
Evidence-based dermatology: number needed to treat and its relation to other risk measures.循证皮肤病学:治疗所需人数及其与其他风险指标的关系。
J Am Acad Dermatol. 2007 Apr;56(4):664-71. doi: 10.1016/j.jaad.2006.08.024. Epub 2006 Oct 27.
5
Communicating the benefits and harms of treatments.传达治疗的益处与危害。
Arch Dis Child. 2008 Aug;93(8):710-3. doi: 10.1136/adc.2008.137083. Epub 2008 May 2.
6
Absolute risk reduction in total mortality with implantable cardioverter defibrillators: analysis of primary and secondary prevention trial data to aid risk/benefit analysis.植入式心脏复律除颤器降低全因死亡率的绝对风险:辅助风险/获益分析的主要和次要预防试验数据分析。
Europace. 2013 Jun;15(6):813-9. doi: 10.1093/europace/eus427. Epub 2013 Jan 30.
7
Number-needed-to-treat (NNT)--needs treatment with care.需治疗人数(NNT)——需谨慎治疗。
Basic Clin Pharmacol Toxicol. 2006 Jul;99(1):12-6. doi: 10.1111/j.1742-7843.2006.pto_412.x.
8
Linking evidence-based medicine therapeutic summary measures to clinical decision analysis.将循证医学治疗总结指标与临床决策分析相联系。
MedGenMed. 2000 Jan 13;2(1):E6.
9
The 'number needed to treat' and the 'adjusted NNT' in health care decision-making.医疗保健决策中的“需治疗人数”与“调整后的需治疗人数”
J Health Serv Res Policy. 1998 Jan;3(1):44-9. doi: 10.1177/135581969800300110.
10
[Using "number needed to treat" to interpret treatment effect].[使用“需治疗人数”来解释治疗效果]
Acta Neurol Taiwan. 2006 Jun;15(2):120-6.

引用本文的文献

1
Changes in frailty, intensive blood pressure treatment, and risks of adverse clinical outcomes: a post hoc analysis of the SPRINT trial.衰弱、强化血压治疗与不良临床结局风险的变化:SPRINT试验的事后分析
BMC Med. 2025 Oct 6;23(1):536. doi: 10.1186/s12916-025-04382-7.
2
Head-to-head comparison of diagnostic test accuracy between biparametric and multiparametric MRI: an updated systematic review and bivariate meta-analysis.双参数与多参数MRI诊断测试准确性的直接比较:一项更新的系统评价和双变量Meta分析
Prostate Cancer Prostatic Dis. 2025 Jul 22. doi: 10.1038/s41391-025-00999-0.
3
A Systematic Review of Interventions for Persons Living With Dementia: The Geriatric ED Guidelines 2.0.
痴呆症患者干预措施的系统评价:老年急诊科指南2.0
medRxiv. 2025 Mar 3:2025.02.28.25323113. doi: 10.1101/2025.02.28.25323113.
4
Risk of Invasive Fungal Infections in Patients With Chronic Lymphocytic Leukemia Treated With Bruton Tyrosine Kinase Inhibitors: A Case-Control Propensity Score-Matched Analysis.接受布鲁顿酪氨酸激酶抑制剂治疗的慢性淋巴细胞白血病患者发生侵袭性真菌感染的风险:一项病例对照倾向评分匹配分析
Open Forum Infect Dis. 2024 Feb 28;11(6):ofae115. doi: 10.1093/ofid/ofae115. eCollection 2024 Jun.
5
Costs and cost-effectiveness of Shamiri, a brief, layperson-delivered intervention for Kenyan adolescents: a randomized controlled trial.沙米里干预肯尼亚青少年的成本和成本效益:一项随机对照试验。
BMC Health Serv Res. 2023 Aug 4;23(1):827. doi: 10.1186/s12913-023-09856-z.
6
Effectiveness of regdanvimab treatment for SARS-CoV-2 delta variant, which exhibited decreased activity: a nationwide real-world multicenter cohort study.针对 SARS-CoV-2 德尔塔变异株(其活性降低)的雷格司亭单抗治疗效果:一项全国范围的真实世界多中心队列研究。
Front Cell Infect Microbiol. 2023 May 15;13:1192512. doi: 10.3389/fcimb.2023.1192512. eCollection 2023.
7
Lamivudine 24-month-long prophylaxis is a safe and efficient choice for the prevention of hepatitis B virus reactivation in HBsAg-negative/HBcAb-positive patients with advanced DLBCL undergoing upfront R-CHOP-21.对于接受初始R-CHOP-21治疗的晚期弥漫性大B细胞淋巴瘤(DLBCL)患者,若其乙肝表面抗原(HBsAg)阴性/乙肝核心抗体(HBcAb)阳性,进行为期24个月的拉米夫定预防治疗是预防乙肝病毒再激活的一种安全有效的选择。
Front Oncol. 2023 Feb 15;13:1130899. doi: 10.3389/fonc.2023.1130899. eCollection 2023.
8
Exercise-based cardiac rehabilitation for coronary heart disease: a meta-analysis.基于运动的冠心病心脏康复:荟萃分析。
Eur Heart J. 2023 Feb 7;44(6):452-469. doi: 10.1093/eurheartj/ehac747.
9
Effect of alirocumab and evolocumab on all-cause mortality and major cardiovascular events: A meta-analysis focusing on the number needed to treat.阿利西尤单抗和依洛尤单抗对全因死亡率和主要心血管事件的影响:一项聚焦于治疗所需人数的荟萃分析。
Front Cardiovasc Med. 2022 Dec 2;9:1016802. doi: 10.3389/fcvm.2022.1016802. eCollection 2022.
10
The use of two Comfort Young Child Formulas in the dietary management of toddlers with functional constipation: a randomized controlled trial.使用两种 Comfort Young Child Formula 在幼儿功能性便秘的饮食管理中:一项随机对照试验。
BMC Pediatr. 2022 Nov 22;22(1):672. doi: 10.1186/s12887-022-03725-0.